Commissioning of portal dosimetry using a novel method for flattening filter-free photon beam in a nontrue beam linear accelerator.

Aim: The aim of this study is to commission and validate the portal dosimetry (PD) system using an indirect method for flattening filter free (FFF) photon beam of the upgraded c-series linear accelerator.

Background: Varian Medical System clinacs with amorphous-silicon portal imager panel (aSi-1000) do not have PD for FFF beams. Recently, our c-series linear accelerator was upgraded to deliver 6MV FFF (6MVFFF) photon beam with the highest dose rate of 1400 monitor unit (MU)/min.

Application of aSi-kVCBCT for Volume Assessment and Dose Estimation: An Offline Adaptive Study for Prostate Radiotherapy.

Objective: The purpose of this study is to develop a method to estimate the dose using amorphous silicon detector panel cone beam computed tomography (aSi-kVCBCT) for the OARs and targets in prostate radiotherapy and to compare with the actual planned dose. Methods: The aSi-kVCBCT is used widely in radiotherapy to verify the patient position before treatment. The advancement in aSi-kVCBCT combined with adaptive software allows us to verify the dose distribution in daily acquired CBCT images.

Multi-isocentric 4π volumetric-modulated arc therapy approach for head and neck cancer.

Objectives: To explore the feasibility of multi-isocentric 4π volumetric-modulated arc therapy (MI4π-VMAT) for the complex targets of head and neck cancers.

Methods: Twenty-five previously treated patients of HNC underwent re-planning to improve the dose distributions with either coplanar VMAT technique (CP-VMAT) or noncoplanar MI4π-VMAT plans. The latter, involving 3-6 noncoplanar arcs and 2-3 isocenters were re-optimized using the same priorities and objectives.

Dosimetric comparison of head and neck cancer patients planned with multivendor volumetric modulated arc therapy technology.

Aim: Purpose of this study is to dosimetrically compare head and neck (H and N) cancer patients planned with multivendor volumetric modulated arc therapy (VMAT) technology. VMAT treatment planning can be done using biological (treatment planning system [TPSB]: Monaco) or physical (TPSP: Eclipse)-based cost function optimization techniques. Planning and dosimetric comparisons were done in both techniques for H and N cases.

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.

The present study addressed the effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin ((1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine), LAF237) on pancreatic beta cell mass in neonatal rats. Newborn rats were treated orally with vildagliptin (60 mg/kg) or vehicle once daily for 19 days starting from postnatal day 2. Pancreatic immunohistochemistry and morphometric analysis were performed to evaluate changes in beta cell mass, cell apoptosis (Apoptag stain) and replication (5'-Bromo-2'-deoxyuridine (BrdU)-incorporation) on days 7, 21, and 33.

Study on the fluorescence characteristics of bromadiolone in aqueous and organized media and application in analysis.

The fluorescence spectroscopic behavior of bromadiolone (anticoagulant rodenticide), a substituted 4-hydroxycoumarin derivative, was investigated in water and in organized media like micelles and cyclodextrins. A detailed study on various photophysical parameters like fluorescence intensity (I(F)), quantum yield (phi), lifetime (tau) and steady state fluorescence anisotropy (r) of bromadiolone in aqueous and in organized media was carried out. Bromadiolone in aqueous solution was observed to be in an aggregated state, thereby showing weak emission due to self-quenching.